A Phenotype–Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir

This publication has 19 references indexed in Scilit:

• Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers
  Clinical Pharmacology & Therapeutics, 2009
• In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates
  Current Medical Research and Opinion, 2009
• Pharmacokinetics, Safety, and Efficacy of Tipranavir Boosted With Ritonavir Alone or in Combination With Other Boosted Protease Inhibitors as Part of Optimized Combination Antiretroviral Therapy in Highly Treatment-Experienced Patients (BI Study 1182.51)
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
• Interaction between lopinavir/ritonavir and warfarin
  CMAJ : Canadian Medical Association Journal, 2007
• Gene and Protein Expression of P-Glycoprotein, MRP1, MRP2, and CYP3A4 in the Small and Large Human Intestine
  Molecular Pharmaceutics, 2007
• Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction Through Cytochrome P-450 Induction
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
• Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers
  Published by Wiley ,2004
• Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail”
  Clinical Pharmacology & Therapeutics, 2003
• Determination of Urinary Metabolites of Caffeine for the Assessment of Cytochrome P4501A2, Xanthine Oxidase, and N-Acetyltransferase Activity in Humans
  Therapeutic Drug Monitoring, 1996
• Variability in caffeine metabolism
  Clinical Pharmacology & Therapeutics, 1983